SCHEMBL6010775

SCHEMBL6010775

C[C@]1(COc2ccc(C(=O)N3CCN(C(=O)OCc4ccc(OC(F)(F)F)cc4)CC3)cc2)Cn2cc([N+](=O)[O-])nc2O1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.71
PTGS1 P23219 1/20 0.61
SLC6A2 P23975 1/20 0.61
SLC6A4 P31645 1/20 0.61
ENPP2 Q13822 6/20 0.47
ATXN2 Q99700 4/20 0.47
CHRM1 P11229 1/20 0.46
CA2 P00918 1/20 0.46
DGAT2 Q96PD7 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LSS P48449 1/20 0.39
HRH3 Q9Y5N1 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38
GAA P10253 1/20 0.37
CACNA1C Q13936 1/20 0.37
SCN5A Q14524 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537692 0.91 KCNH2 (0.71) KCNH2PTGS1SLC6A2SLC6A4ENPP2
SCHEMBL5544110 0.91 KCNH2 (0.71) KCNH2PTGS1SLC6A2SLC6A4ENPP2
SCHEMBL5539089 0.91 KCNH2 (0.71) KCNH2PTGS1SLC6A2SLC6A4ENPP2
SCHEMBL5534646 0.91 KCNH2 (0.72) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL5534642 0.91 KCNH2 (0.72) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL5539481 0.89 KCNH2 (0.75) KCNH2PTGS1SLC6A2SLC6A4ENPP2
SCHEMBL5539475 0.89 KCNH2 (0.75) KCNH2PTGS1SLC6A2SLC6A4ENPP2
SCHEMBL6010709 0.89 KCNH2 (0.69) KCNH2PTGS1SLC6A2SLC6A4ENPP2
SCHEMBL6012358 0.88 KCNH2 (0.65) KCNH2PTGS1SLC6A2SLC6A4ENPP2
SCHEMBL6010965 0.88 KCNH2 (0.64) KCNH2PTGS1SLC6A2SLC6A4ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KCNH2 3503/4885PTGS1 3838/4885SLC6A2 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.